Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

Figures & data

Table 1 Main studies of the effectiveness of adding bevacizumab to standard chemotherapy in elderly patients with metastatic colorectal cancer

Reference	N %	Backbone CT	Line	RR %	PFS (months)	OS (months)
Kabbinavar et al^Citation20	139 CT/B 137 CT	IFL/FL	1	30.9 vs 25.5 NS	9.2 vs 6.2 HR 0.51 P<0.0001	18.7 vs 12.6 HR 0.69 P=0.015
Cassidy et al^Citation21	362 CT/B 350 CT	IFL/FL/XELOX/FOLFOX	1/2	NA	9.2 vs 6.4 HR 0.54 P<0.0001	17.4 vs 14.1 HR 0.79 P=0.005
Cunningham et al^Citation22	140 CT/B 140 CT	Capecitabine	1	19.3 vs 10.0 P=0.04	9.1 vs 5.1 HR 0.53 P<0.001	20.7 vs 16.8 HR 0.79 P=0.18

Abbreviations: CT, chemotherapy; B, bevacizumab; RR, response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; NA, not applicable; IFL, irinotecan/fluorouracil/levoleucovorin; FL, fluorouracil/levoleucovorin; XELOX, capecitabine/oxaliplatin; FOLFOX, 5-fluorouracil/leucovorin/oxaliplatin.

CassidyJSaltzLBGiantonioBJEffect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesJ Cancer Res Clin Oncol2010136573774319904559

 PubMed Web of Science ®Google Scholar

CunninghamDLangIMarcuelloEBevacizumab plus capecit-abine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialLancet Oncol201314111077108524028813

 PubMed Web of Science ®Google Scholar

KozloffMYoodMUBerlinJClinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort studyOncologist200914986287019726453

 PubMed Web of Science ®Google Scholar